RDHL.TA - RedHill Biopharma Ltd.

Tel Aviv - Tel Aviv Delayed Price. Currency in ILS
312.40
+4.10 (+1.33%)
At close: 5:24PM IST
Stock chart is not supported by your current browser
Previous Close308.30
Open312.80
Bid309.00 x 400800
Ask312.50 x 100
Day's Range309.00 - 315.10
52 Week Range163.00 - 529.90
Volume160,362
Avg. Volume624,488
Market Cap886.238M
Beta (3Y Monthly)0.69
PE Ratio (TTM)N/A
EPS (TTM)-0.19
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est26.00
  • GlobeNewswirelast month

    RedHill Biopharma Announces Fifth U.S. Patent Covering TALICIA® for H. pylori Infection

    Notice of Allowance received and, once granted, the new U.S. patent is expected to be valid until 2034NDA submission is expected in H1/2019, with eligibility for 6-month.

  • Reuters2 months ago

    Tel Aviv shares slide 5 pct in worst day since 2011

    Israeli stocks slid on Sunday, posting their worst daily performance in more than seven years in a broad selloff that followed declines on Wall Street late last week. The Tel Aviv 125 share index closed ...

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces Closing of $20 Million Underwritten Offering

    TEL-AVIV, Israel and RALEIGH, N.C., Dec. 11, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced the closing of its previously announced underwritten public offering for a total number of 2,857,143 American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, at a public offering price of $7.00 per ADS. The Company has also granted the underwriters a 30-day option to purchase up to 428,571 additional ADSs at the public offering price.

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces Pricing of $20 Million Underwritten Offering

    TEL-AVIV, Israel and RALEIGH, N.C., Dec. 06, 2018 -- RedHill Biopharma Ltd. (Nasdaq:RDHL) (Tel-Aviv Stock Exchange:RDHL) (“RedHill” or the “Company”), a specialty.

  • GlobeNewswire2 months ago

    RedHill Biopharma Announces Proposed Public Offering of its American Depositary Shares

    TEL-AVIV, Israel and RALEIGH, N.C., Dec. 04, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that it intends to offer its American Depositary Shares (“ADSs”), each representing ten of its ordinary shares, in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the number of ADSs offered to the public. The Company intends to use the net proceeds from the offering, together with its existing cash and cash equivalents, to fund preparations for TALICIA® (H. pylori) commercial launch and commercialization activities, clinical development programs, including initiation of a pivotal Phase III study with RHB-204 for NTM, preparations for a second Phase III study with RHB-104 for Crohn’s disease and for acquisitions and general corporate purposes.

  • Reuters3 months ago

    RedHill Biopharma's antibiotic succeeds in late-stage study

    Israel-based RedHill Biopharma Ltd said on Monday its combination antibiotic met the main goal of a late-stage study testing the drug in patients with a type of bacterial infection that affects the stomach and small intestine. The drug, Talicia, eradicated the Helicobacter pylori infection in 84 percent of patients, compared with 58 percent that received a combination of two commonly used antibiotics. RedHill estimates 2.5 million patients are treated annually for H. pylori bacterial infections in the United States.

  • GlobeNewswire3 months ago

    RedHill Biopharma Announces Positive Top-Line Results from Confirmatory Phase 3 Study with TALICIA® for H. pylori Infection

    The ERADICATE Hp2 confirmatory Phase 3 study successfully met its primary endpoint of H. pylori eradication (84% vs. 58%) with high degree of statistical significance.

  • GlobeNewswire3 months ago

    RedHill Biopharma to Present at BMO 2018 Prescriptions for Success Healthcare Conference

    TEL-AVIV, Israel and RALEIGH, N.C., Nov. 29, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on proprietary drugs for gastrointestinal diseases, today announced that Mr. Dror Ben-Asher, chief executive officer of RedHill, will present a corporate overview at the BMO 2018 Prescriptions for Success Healthcare Conference on Wednesday, December 12, 2018, at 3:00 p.m. EST at the Mandarin Oriental Hotel, New York.